What is the catalog number for Doxifluridine-d2?

The catalog number for Doxifluridine-d2 is HY-B0021S.

What sizes are available for Doxifluridine-d2?

Doxifluridine-d2 is available in the following size(s): 5 mg.

Is Doxifluridine-d2 in stock?

Doxifluridine-d2 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Doxifluridine-d2?

Doxifluridine-d2 is manufactured by QuantiMol.

What is the estimated delivery time for Doxifluridine-d2?

Estimated delivery time for Doxifluridine-d2 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Doxifluridine-d2?

The safety data sheet for Doxifluridine-d2 is available here: http://file.medchemexpress.com/batch_PDF/HY-B0021S/.

Doxifluridine-d2

Doxifluridine-d2 is the deuterium labeled Doxifluridine[1]. Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.

Product Specifications

CAS Number

84258-25-3

Product Name Alternative

Ro 21-9738-d2; 5-Fluoro-5'-deoxyuridine-d2; 5'-DFUR-d2

UNSPSC

12352005

Target

Nucleoside Antimetabolite/Analog

Type

Isotope-Labeled Compounds

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@@](N2C(NC(C(F)=C2)=O)=O)([H])O[C@@H]([C@H]1O)C([2H])[2H]

Molecular Formula

C9H9D2FN2O5

Molecular Weight

248.20

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Dipartimento di Chimica, Università degli Studi della Basilicata, Potenza, In vitro toxicity of N3-methyl-5'-deoxy-5-fluorouridine, a novel metabolite of doxifluridine: a bioanalytical investigation. J Pharm Biomed Anal. 1998 May;17 (1) :11-6.|[3]Baek IH, Lee BY, Kim MS, Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs. Eur J Drug Metab Pharmacokinet. 2013 Apr 7.|[4]Yoshikawa T, Tsuburaya A, Shimada K, A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 200912 (4) :212-8.